Novel tau fragments in cerebrospinal fluid: relation to tangle pathology and cognitive decline in Alzheimer’s disease
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
Tau is an axonal microtubule-binding protein. Tau pathology in brain and increased tau concentration in the cerebrospinal fluid (CSF) are hallmarks of Alzheimer's disease (AD). Most of tau in CSF is present as fragments. We immunoprecipitated tau from CSF and identified several endogenous peptides ending at amino acid (aa) 123 or 224 using high-resolution mass spectrometry. We raised neo-epitope-specific antibodies against tau fragments specifically ending at aa 123 and 224, respectively. With these antibodies, we performed immunohistochemistry on brain tissue and designed immunoassays measuring N-123, N-224, and x-224 tau. Immunoassays were applied to soluble brain fractions from pathologically confirmed subjects (81 AD patients, 33 controls), CSF from three cross-sectional and two longitudinal cohorts (a total of 133 AD, 38 MCI, 20 MCI-AD, 31 PSP, 15 CBS patients, and 91 controls), and neuronally- and peripherally-derived extracellular vesicles (NDEVs and PDEVs, respectively) in serum from four AD patients and four controls. Anti-tau 224 antibody stained neurofibrillary tangles and neuropil threads, while anti-tau 123 only showed weak cytoplasmic staining in AD. N-224 tau was lower in the AD soluble brain fraction compared to controls, while N-123 tau showed similar levels. N-224 tau was higher in AD compared to controls in all CSF cohorts (p < 0.001), but not N-123 tau. Decrease in cognitive performance and conversion from MCI to AD were associated with increased baseline CSF levels of N-224 tau (p < 0.0001). N-224 tau concentrations in PSP and CBS were significantly lower than in AD (p < 0.0001) and did not correlate to t-tau and p-tau. In a longitudinal cohort, CSF N-224 tau levels were stable over 6 months, with no significant effect of treatment with AChE inhibitors. N-224 tau was present in NDEVs, while N-123 tau showed comparable concentrations in both vesicle types. We suggest that N-123 tau is produced both in CNS and PNS and represents a general marker of tau metabolism, while N-224 tau is neuron-specific, present in the tangles, secreted in CSF, and upregulated in AD, suggesting a link between tau cleavage and propagation, tangle pathology, and cognitive decline.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures









Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For example, the CSF t-tau immunoassay used here relies on a combination of monoclonal antibodies with epitopes in the mid-protein region.In contrast, the plasma t-tau assay detects epitopes going from the N-terminal region to the more distal amino acid 224.39”
From Plasma Tau and Neurofilament Light in Frontotemporal Lobar Degeneration and Alzheimer Disease (2021) · cites this paper as [39]
Experimental — accuracy not yet measuredIn the citing paper
“In AD, tau becomes truncated and hyperphosphorylated (3), which can increase the risk for tau to aggregate into the paired helical filaments (PHF) that are found in neurofibrillary tangles (NFT) and neuropil treads in the brains of patients with AD (1).”
From Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive tau PET in Alzheimer's disease (2020) · cites this paper as [3]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Mild cognitive impairment as a diagnostic entity
Petersen, R. C. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01388.x · Cited by 7,864
A new rating scale for Alzheimer's disease
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.11.1356 · Cited by 4,175
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70090-0 · Cited by 3,321
Self-citationScheltens, P., Blennow, K., Breteler, M. M. B., de Strooper, B., Frisoni, G. B., Salloway, S., & Van der Flier, W. M. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01124-1 · Cited by 3,125
Self-citationOlsson, B., Lautner, R., Andreasson, U., Öhrfelt, A., Portelius, E., Bjerke, M., Hölttä, M., Rosén, C., Olsson, C., Strobel, G., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00070-3 · Cited by 2,049
Self-citationCriteria for the diagnosis of corticobasal degeneration
Armstrong, M. J., Litvan, I., Lang, A. E., Bak, T. H., Bhatia, K. P., Borroni, B., Boxer, A. L., Dickson, D. W., Grossman, M., Hallett, M., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e31827f0fd1 · Cited by 1,904 · cited 6×
“Aβsubjects were 15 in the PSP and seven in the CBS group.”
BackgroundInfluential
Cited by
A current view on Tau protein phosphorylation in Alzheimer's disease
Wegmann, S., Biernat, J., & Mandelkow, E. (2021) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2021.03.003 · Cited by 456
Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer’s disease
Barthélemy, N. R., Horie, K., Sato, C., & Bateman, R. J. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20200861 · Cited by 437
Suárez‐Calvet, M., Karikari, T. K., Ashton, N. J., Lantero Rodríguez, J., Milà‐Alomà, M., Gispert, J. D., Salvadó, G., Minguillon, C., Fauria, K., Shekari, M., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.202012921 · Cited by 401
Self-citationMattsson-Carlgren, N., Andersson, E., Janelidze, S., Ossenkoppele, R., Insel, P., Strandberg, O., Zetterberg, H., Rosen, H. J., Rabinovici, G., Chai, X., et al. (2020) · Science Advances · doi:10.1126/sciadv.aaz2387 · Cited by 359
Self-citationBlood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility
Karikari, T. K., Ashton, N. J., Brinkmalm, G., Brum, W. S., Benedet, A. L., Montoliu-Gaya, L., Lantero-Rodriguez, J., Pascoal, T. A., Suárez-Calvet, M., Rosa-Neto, P., et al. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-022-00665-2 · Cited by 329
Self-citationCSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer’s disease
Horie, K., Salvadó, G., Barthélemy, N. R., Janelidze, S., Li, Y., He, Y., Saef, B., Chen, C. D., Jiang, H., Strandberg, O., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02443-z · Cited by 249
Self-citationRösler, T. W., Tayaranian Marvian, A., Brendel, M., Nykänen, N.-P., Höllerhage, M., Schwarz, S. C., Hopfner, F., Koeglsperger, T., Respondek, G., Schweyer, K., et al. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2019.101644 · Cited by 224
Role of Exosomes in Central Nervous System Diseases
Liu, W., Bai, X., Zhang, A., Huang, J., Xu, S., & Zhang, J. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00240 · Cited by 221
Tau Protein Interaction Partners and Their Roles in Alzheimer’s Disease and Other Tauopathies
Sinsky, J., Pichlerova, K., & Hanes, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179207 · Cited by 220
“showed that in tauopathy, calpain-2 cleaves tau at Lys224 [408], a fragment enriched in CSF tau pool in pathological conditions [409].”
BackgroundPlasma phospho-tau in Alzheimer’s disease: towards diagnostic and therapeutic trial applications
Gonzalez-Ortiz, F., Kac, P. R., Brum, W. S., Zetterberg, H., Blennow, K., & Karikari, T. K. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00605-8 · Cited by 214
Self-citationRoles of extracellular vesicles in the aging microenvironment and age‐related diseases
Yin, Y., Chen, H., Wang, Y., Zhang, L., & Wang, X. (2021) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12154 · Cited by 196
Self-citationFrom the prion-like propagation hypothesis to therapeutic strategies of anti-tau immunotherapy
Colin, M., Dujardin, S., Schraen-Maschke, S., Meno-Tetang, G., Duyckaerts, C., Courade, J.-P., & Buée, L. (2020) · Acta Neuropathologica · doi:10.1007/s00401-019-02087-9 · Cited by 187
An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders
Ashton, N. J., Hye, A., Rajkumar, A. P., Leuzy, A., Snowden, S., Suárez-Calvet, M., Karikari, T. K., Schöll, M., La Joie, R., Rabinovici, G. D., et al. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0348-0 · Cited by 185
Self-citationCSF tau microtubule binding region identifies tau tangle and clinical stages of Alzheimer’s disease
Horie, K., Barthélemy, N. R., Sato, C., & Bateman, R. J. (2021) · Brain · doi:10.1093/brain/awaa373 · Cited by 180
“sites, including phosphorylation, in addition to multiple truncation sites (Meredith et al., 2013; Sato et al., 2018; Barthélemy et al., 2019; Cicognola et al., 2019; Blennow et al., 2020).”
BackgroundAmyloid β-protein and beyond: the path forward in Alzheimer’s disease
Walsh, D. M., & Selkoe, D. J. (2020) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2020.02.003 · Cited by 157
Limorenko, G., & Lashuel, H. A. (2022) · Chemical Society Reviews · doi:10.1039/d1cs00127b · Cited by 162
Barthélemy, N. R., Saef, B., Li, Y., Gordon, B. A., He, Y., Horie, K., Stomrud, E., Salvadó, G., Janelidze, S., Sato, C., et al. (2023) · Nature Aging · doi:10.1038/s43587-023-00380-7 · Cited by 153
Self-citationPlasma Tau and Neurofilament Light in Frontotemporal Lobar Degeneration and Alzheimer Disease
Illán-Gala, I., Lleo, A., Karydas, A., Staffaroni, A. M., Zetterberg, H., Sivasankaran, R., Grinberg, L. T., Spina, S., Kramer, J. H., Ramos, E. M., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000011226 · Cited by 150
Self-citationKarikari, T. K., Emeršič, A., Vrillon, A., Lantero‐Rodriguez, J., Ashton, N. J., Kramberger, M. G., Dumurgier, J., Hourregue, C., Čučnik, S., Brinkmalm, G., et al. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12236 · Cited by 143
“In the discovery cohort, Aβ42, Mid-p-tau181, and total-tau were measured using the INNOTEST® β-AMYLOID(1-42), PHOSPHOTAU(181P), and hTAU Ag ELISAs.”
MethodSelf-citationAshton, N. J., Leuzy, A., Karikari, T. K., Mattsson-Carlgren, N., Dodich, A., Boccardi, M., Corre, J., Drzezga, A., Nordberg, A., Ossenkoppele, R., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05253-y · Cited by 142
Self-citationLeuzy, A., Janelidze, S., Mattsson-Carlgren, N., Palmqvist, S., Jacobs, D., Cicognola, C., Stomrud, E., Vanmechelen, E., Dage, J. L., & Hansson, O. (2021) · Neurology · doi:10.1212/wnl.0000000000012727 · Cited by 128
Self-citationMontoliu-Gaya, L., Benedet, A. L., Tissot, C., Vrillon, A., Ashton, N. J., Brum, W. S., Lantero-Rodriguez, J., Stevenson, J., Nilsson, J., Sauer, M., et al. (2023) · Nature Aging · doi:10.1038/s43587-023-00405-1 · Cited by 122
Self-citationGaetani, L., Paolini Paoletti, F., Bellomo, G., Mancini, A., Simoni, S., Di Filippo, M., & Parnetti, L. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.09.011 · Cited by 108
Self-citationMullane, K., & Williams, M. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.113945 · Cited by 105
An update on fluid biomarkers for neurodegenerative diseases: recent success and challenges ahead
Simrén, J., Ashton, N. J., Blennow, K., & Zetterberg, H. (2020) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2019.11.019 · Cited by 107
Self-citationPropagation of Tau Pathology: Integrating Insights From Postmortem and In Vivo Studies
Vogels, T., Leuzy, A., Cicognola, C., Ashton, N. J., Smolek, T., Novak, M., Blennow, K., Zetterberg, H., Hromadka, T., Zilka, N., et al. (2020) · Biological Psychiatry · doi:10.1016/j.biopsych.2019.09.019 · Cited by 95
Self-citationBrain Derived Exosomes Are a Double-Edged Sword in Alzheimer’s Disease
Song, Z., Xu, Y., Deng, W., Zhang, L., Zhu, H., Yu, P., Qu, Y., Zhao, W., Han, Y., & Qin, C. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.00079 · Cited by 104
Cerebrospinal fluid tau fragment correlates with tau PET: a candidate biomarker for tangle pathology
Blennow, K., Chen, C., Cicognola, C., Wildsmith, K. R., Manser, P. T., Bohorquez, S. M. S., Zhang, Z., Xie, B., Peng, J., Hansson, O., et al. (2020) · Brain · doi:10.1093/brain/awz346 · Cited by 105
Self-citationPlasma biomarkers predict Alzheimer’s disease before clinical onset in Chinese cohorts
Cai, H., Pang, Y., Fu, X., Ren, Z., & Jia, L. (2023) · Nature Communications · doi:10.1038/s41467-023-42596-6 · Cited by 101
Current Status of Clinical Trials on Tau Immunotherapies
Ji, C., & Sigurdsson, E. M. (2021) · Drugs · doi:10.1007/s40265-021-01546-6 · Cited by 96
Current advances in plasma and cerebrospinal fluid biomarkers in Alzheimer's disease
Leuzy, A., Cullen, N. C., Mattsson-Carlgren, N., & Hansson, O. (2021) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000904 · Cited by 92
Self-citationTau immunotherapies: Lessons learned, current status and future considerations
Sandusky-Beltran, L. A., & Sigurdsson, E. M. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108104 · Cited by 90
Biomarker potential of brain‐secreted extracellular vesicles in blood in Alzheimer's disease
Badhwar, A., & Haqqani, A. S. (2020) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1002/dad2.12001 · Cited by 87
Islam, T., Hill, E., Abrahamson, E. E., Servaes, S., Smirnov, D. S., Zeng, X., Sehrawat, A., Chen, Y., Kac, P. R., Kvartsberg, H., et al. (2025) · Nature Medicine · doi:10.1038/s41591-024-03400-0 · Cited by 85
Self-citationHuman Tau Isoforms and Proteolysis for Production of Toxic Tau Fragments in Neurodegeneration
Boyarko, B., & HOOK, V. Y. H. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.702788 · Cited by 83
Anti-Tau Trials for Alzheimer's Disease: A Report from the EU/US/CTAD Task Force
Cummings, J., Blennow, K., Johnson, K., Keeley, M., Bateman, R. J., Molinuevo, J. L., Touchon, J., Aisen, P., & Vellas, B. (2019) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2019.14 · Cited by 71
Self-citationLeuzy, A., Ashton, N. J., Mattsson-Carlgren, N., Dodich, A., Boccardi, M., Corre, J., Drzezga, A., Nordberg, A., Ossenkoppele, R., Zetterberg, H., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05258-7 · Cited by 69
Self-citationd’Abramo, C., D'adamio, L., & Giliberto, L. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10030116 · Cited by 79
Muraoka, S., Jedrychowski, M. P., Tatebe, H., DeLeo, A. M., Ikezu, S., Tokuda, T., Gygi, S. P., Stern, R. A., & Ikezu, T. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.01059 · Cited by 60
Ultrasensitive tau biosensor cells detect no seeding in Alzheimer’s disease CSF
Hitt, B. D., Vaquer-Alicea, J., Manon, V. A., Beaver, J. D., Kashmer, O. M., Garcia, J. N., & Diamond, M. I. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01185-8 · Cited by 71
Development and validation of a high‐sensitivity assay for measuring p217+tau in plasma
Triana‐Baltzer, G., Moughadam, S., Slemmon, R., Van Kolen, K., Theunis, C., Mercken, M., & Kolb, H. C. (2021) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1002/dad2.12204 · Cited by 64
Clinical Spectrum of Tauopathies
Olfati, N., Shoeibi, A., & Litvan, I. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.944806 · Cited by 71
Xu, X., Iqbal, Z., Xu, L., Wen, C., Duan, L., Xia, J., Yang, N., Zhang, Y., & Liang, Y. (2024) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13610 · Cited by 68
Enhancing Top-Down Proteomics of Brain Tissue with FAIMS
Fulcher, J. M., Makaju, A., Moore, R. J., Zhou, M., Bennett, D. A., De Jager, P. L., Qian, W.-J., Paša-Tolić, L., & Petyuk, V. A. (2021) · Journal of Proteome Research · doi:10.1021/acs.jproteome.1c00049 · Cited by 68
Characterization of tau binding by gosuranemab
Sopko, R., Golonzhka, O., Arndt, J., Quan, C., Czerkowicz, J., Cameron, A., Smith, B., Murugesan, Y., Gibbons, G., Kim, S.-J., et al. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105120 · Cited by 63
Recommendations for reproducibility of cerebrospinal fluid extracellular vesicle studies
Sandau, U. S., Magaña, S. M., Costa, J., Nolan, J. P., Ikezu, T., Vella, L. J., Jackson, H. K., Moreira, L. R., Palacio, P. L., Hill, A. F., et al. (2023) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12397 · Cited by 65
P‐tau235: a novel biomarker for staging preclinical Alzheimer’s disease
Lantero‐Rodriguez, J., Snellman, A., Benedet, A. L., Milà‐Alomà, M., Camporesi, E., Montoliu‐Gaya, L., Ashton, N. J., Vrillon, A., Karikari, T. K., Gispert, J. D., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202115098 · Cited by 56
Self-citationKaur, P., Khera, A., Alajangi, H. K., Sharma, A., Jaiswal, P. K., Singh, G., & Barnwal, R. P. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-03164-z · Cited by 59
Kac, P. R., González‐Ortiz, F., Emeršič, A., Dulewicz, M., Koutarapu, S., Turton, M., An, Y., Smirnov, D. S., Kulczyńska‐Przybik, A., Varma, V. R., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46876-7 · Cited by 58
Self-citationSchedin‐Weiss, S., Gaunitz, S., Sui, P., Chen, Q., Haslam, S. M., Blennow, K., Winblad, B. G., Dell, A., & Tjernberg, L. O. (2020) · FEBS Journal · doi:10.1111/febs.15197 · Cited by 57
Self-citationObrocki, P., Khatun, A., Ness, D., Senkevich, K. A., Hanrieder, J., Capraro, F., Mattsson, N., Andréasson, U., Portelius, E., Ashton, N. J., et al. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00586-6 · Cited by 56
Self-citationWeisová, P., Cehlár, O., Škrabana, R., Žilková, M., Filipčík, P., Kováčech, B., Prčina, M., Wojčiaková, Ľ., Fialová, Ľ., Smolek, T., et al. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0770-y · Cited by 52
Comparison of CSF phosphorylated tau 181 and 217 for cognitive decline
Mielke, M. M., Aakre, J. A., Algeciras‐Schimnich, A., Proctor, N. K., Machulda, M. M., Eichenlaub, U., Knopman, D. S., Vemuri, P., Graff‐Radford, J., Jack, C. R., et al. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12415 · Cited by 55
N-terminal and mid-region tau fragments as fluid biomarkers in neurological diseases
Snellman, A., Lantero-Rodriguez, J., Emeršič, A., Vrillon, A., Karikari, T. K., Ashton, N. J., Gregorič Kramberger, M., Čučnik, S., Paquet, C., Rot, U., et al. (2022) · Brain · doi:10.1093/brain/awab481 · Cited by 51
Self-citationLiu, X., Ye, M., & Ma, L. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.1022821 · Cited by 53
Simoes, S., Neufeld, J. L., Triana-Baltzer, G., Moughadam, S., Chen, E. I., Kothiya, M., Qureshi, Y. H., Patel, V., Honig, L. S., Kolb, H., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aba6334 · Cited by 51
Knockin’ on heaven’s door: Molecular mechanisms of neuronal tau uptake
De La‐Rocque, S., Moretto, E., Butnaru, I., & Schiavo, G. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15144 · Cited by 39
Blennow, K., & Zetterberg, H. (2019) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2019.07.006 · Cited by 50
Self-citationLantero-Rodriguez, J., Salvadó, G., Snellman, A., Montoliu-Gaya, L., Brum, W. S., Benedet, A. L., Mattsson-Carlgren, N., Tideman, P., Janelidze, S., Palmqvist, S., et al. (2024) · Molecular Neurodegeneration · doi:10.1186/s13024-024-00707-x · Cited by 41
Self-citationAmadoro, G., Latina, V., Corsetti, V., & Calissano, P. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2019.165584 · Cited by 43
Goodwin, M. S., Sinyavskaya, O., Burg, F., O’Neal, V., Ceballos-Diaz, C., Cruz, P. E., Lewis, J., Giasson, B. I., Davies, P., Golde, T. E., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.10.007 · Cited by 44
Tau protein profiling in tauopathies: a human brain study
Lantero‐Rodriguez, J., Camporesi, E., Montoliu‐Gaya, L., Gobom, J., Piotrowska, D., Olsson, M., Matečko‐Burmann, I., Becker, B., Brinkmalm, A., Burmann, B. M., et al. (2024) · Molecular Neurodegeneration · doi:10.1186/s13024-024-00741-9 · Cited by 47
Self-citationMass Spectrometry for Neurobiomarker Discovery: The Relevance of Post-Translational Modifications
Azevedo, R., Jacquemin, C., Villain, N., Fenaille, F., Lamari, F., & Bécher, F. (2022) · Cells · doi:10.3390/cells11081279 · Cited by 46
The Challenge of Disease-Modifying Therapies in Parkinson’s Disease: Role of CSF Biomarkers
Paoletti, F. P., Gaetani, L., & Parnetti, L. (2020) · Biomolecules · doi:10.3390/biom10020335 · Cited by 43
Self-citationCorsetti, V., Borreca, A., Latina, V., Giacovazzo, G., Pignataro, A., Krashia, P., Natale, F., Cocco, S., Rinaudo, M., Malerba, F., et al. (2020) · Brain Communications · doi:10.1093/braincomms/fcaa039 · Cited by 42
Tau truncation in the pathogenesis of Alzheimer’s disease: a narrative review
Chu, D., Yang, X., Wang, J., Zhou, Y., Gu, J., Miao, J., Wu, F., & Liu, F. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.385853 · Cited by 40
Kim, K. Y., Shin, K. Y., & Chang, K.-A. (2021) · Biomolecules · doi:10.3390/biom11070980 · Cited by 35
Mengel, D., Liu, W., Glynn, R. J., Selkoe, D. J., Strydom, A., Lai, F., Rosas, H. D., Torres, A., Patsiogiannis, V., Skotko, B. G., et al. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00593-7 · Cited by 38
A new generation of AD biomarkers: 2019 to 2021
Hawksworth, J. I., Fernández, E., & Gevaert, K. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101654 · Cited by 37
Yang, J., Shen, N., Shen, J., Yang, Y., & Li, H.-L. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03867-x · Cited by 36
Plasma NT1 Tau is a Specific and Early Marker of Alzheimer's Disease
Mengel, D., Janelidze, S., Glynn, R. J., Liu, W., Hansson, O., & Walsh, D. M. (2020) · Annals of Neurology · doi:10.1002/ana.25885 · Cited by 36
Self-citationBarthélemy, N. R., Toth, B., Manser, P. T., Bohorquez, S. M. S., Teng, E., Keeley, M., Bateman, R. J., Weimer, R. M., & Wildsmith, K. R. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210677 · Cited by 36
Self-citationWojdała, A. L., Bellomo, G., Gaetani, L., Teunissen, C. E., Parnetti, L., & Chiasserini, D. (2025) · Nature Communications · doi:10.1038/s41467-024-54878-8 · Cited by 34
Self-citationTaha, H. B. (2025) · npj Dementia · doi:10.1038/s44400-024-00002-y · Cited by 34
Latina, V., Giacovazzo, G., Cordella, F., Balzamino, B. O., Micera, A., Varano, M., Marchetti, C., Malerba, F., Florio, R., Ercole, B. B., et al. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01138-1 · Cited by 34
Muraoka, S., DeLeo, A. M., Yang, Z., Tatebe, H., Takamatsu-Yukawa, K., Ikezu, S., Tokuda, T., Issadore, D., Stern, R. A., & Ikezu, T. (2021) · Aging and Disease · doi:10.14336/ad.2020.0908 · Cited by 34
Simrén, J., Brum, W. S., Ashton, N. J., Benedet, A. L., Karikari, T. K., Kvartsberg, H., Sjons, E., Lussier, F. Z., Chamoun, M., Stevenson, J., et al. (2022) · Alzheimer's Research & Therapy · doi:10.1186/s13195-022-01142-0 · Cited by 35
Self-citationEllis, M. J., Lekka, C., Holden, K. L., Tulmin, H., Seedat, F., O'Brien, D. P., Dhayal, S., Zeissler, M., Knudsen, J. G., Kessler, B. M., et al. (2024) · Acta Neuropathologica · doi:10.1007/s00401-024-02729-7 · Cited by 34
The Role of Extracellular Matrix Components in the Spreading of Pathological Protein Aggregates
Moretto, E., Stuart, S., Surana, S., Vargas, J. N. S., & Schiavo, G. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.844211 · Cited by 32
Brown, J., Camporesi, E., Lantero‐Rodriguez, J., Olsson, M., Wang, A., Medem, B., Zetterberg, H., Blennow, K., Karikari, T. K., Wall, M. J., et al. (2023) · Acta Neuropathologica Communications · doi:10.1186/s40478-023-01562-5 · Cited by 34
Self-citationDistinct Neurotoxic Effects of Extracellular Tau Species in Primary Neuronal-Glial Cultures
Pampuščenko, K., Morkūnienė, R., Krasauskas, L., Smirnovas, V., Tomita, T., & Borutaitė, V. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-02150-7 · Cited by 32
Solje, E., Benussi, A., Buratti, E., Remes, A. M., Haapasalo, A., & Borroni, B. (2021) · Diagnostics · doi:10.3390/diagnostics11050788 · Cited by 30
Arya, S., Claud, S. L., Cantrell, K. L., & Bowers, M. T. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00516 · Cited by 28
Fluid Biomarkers for Chronic Traumatic Encephalopathy
Shahim, P., Gill, J., Blennow, K., & Zetterberg, H. (2020) · Seminars in Neurology · doi:10.1055/s-0040-1715095 · Cited by 27
Self-citationRole of Body-Fluid Biomarkers in Alzheimer’s Disease Diagnosis
Nguyen, T. T., Ta, Q. T. H., Nguyen, T. K. O., Nguyen, T. T. D., & Giau, V. V. (2020) · Diagnostics · doi:10.3390/diagnostics10050326 · Cited by 27
Cyclosporine A (CsA) prevents synaptic impairment caused by truncated tau by caspase-3
Tapia-Monsalves, C., Olesen, M. A., Villavicencio-Tejo, F., & Quintanilla, R. A. (2023) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2023.103861 · Cited by 26
Hoglund, Z. T., Ruiz‐Uribe, N. E., del Sastre, E., Woost, B., Bader, E., Bailey, J. J., Hyman, B. T., Zwang, T. J., & Bennett, R. E. (2024) · Acta Neuropathologica · doi:10.1007/s00401-024-02751-9 · Cited by 25
Triana‐Baltzer, G., Kolen, K. V., Theunis, C., Moughadam, S., Slemmon, R., Mercken, M. H., Galpern, W. R., Sun, H. F., & Kolb, H. C. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200463 · Cited by 25
Biomarkers and Tools for Predicting Alzheimer’s Disease in the Preclinical Stage
Li, T.-R., Yang, Q. Z., Hu, X., & Han, Y. (2021) · Current Neuropharmacology · doi:10.2174/1570159x19666210524153901 · Cited by 24
Theofilas, P., Piergies, A. M. H., Oh, I. M., Lee, Y. B., Li, S. H., Pereira, F. L., Petersen, C., Ehrenberg, A. J., Eser, R. A., Ambrose, A. J., et al. (2022) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12819 · Cited by 23
Soleymani, T., Chen, T.-Y., Gonzalez‐Kozlova, E., & Dogra, N. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1156821 · Cited by 24
Alzheimer's Disease Biomarker Analysis Using Targeted Mass Spectrometry
Gobom, J., Brinkmalm, A., Brinkmalm, G., Blennow, K., & Zetterberg, H. (2024) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2024.100721 · Cited by 23
Self-citationMonteiro-Reis, S., Carvalho-Maia, C., Bart, G., Vainio, S. J., Pedro, J., Silva, E. R., Sales, G., Henrique, R., & Jerónimo, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22063267 · Cited by 21
“Of note, both Aβ and tau are secreted by neurons through the release of EVs [12,26,36,56,90].”
BackgroundTaheri, M., Aslani, S., Ghafouri, H., Mohammadi, A., Moghaddam, V. A., Moradi, N., & Naeimi, H. (2022) · BMC Chemistry · doi:10.1186/s13065-022-00799-w · Cited by 21
Arastoo, M., Lofthouse, R. A., Penny, L. K., Harrington, C. R., Porter, A., Wischik, C. M., & Palliyil, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228673 · Cited by 21
Degradomics in Biomarker Discovery
Grozdanić, M., Vidmar, R., Vizovišek, M., & Fonovič, M. (2019) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201800138 · Cited by 21
Tau: a biomarker of Huntington’s disease
Lepinay, E., & Cicchetti, F. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02230-9 · Cited by 19
Tanycytic degeneration impairs tau clearance and contributes to Alzheimer’s disease pathology
Sauvé, F., Gomez-Martínez, R., Mbouamboua, Y., Ternier, G., Nampoothiri, S. S., Dupré, E., Garcia, L., Couralet, M., Dewisme, J., Lebouvier, T., et al. (2026) · Cell Press Blue · doi:10.1016/j.cpblue.2026.100003 · Cited by 19
Horie, K., Li, Y., Barthélemy, N. R., Gordon, B. A., Hassenstab, J. J., Benzinger, T. L. S., Fagan, A. M., Morris, J. C., Karch, C. M. M., Xiong, C., et al. (2023) · Annals of Neurology · doi:10.1002/ana.26620 · Cited by 18
Anti-tau antibodies targeting a conformation-dependent epitope selectively bind seeds
Hitt, B. D., Gupta, A., Singh, R., Yang, T., Beaver, J. D., Shang, P., White, C. L., Joachimiak, Ł. A., & Diamond, M. I. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.105252 · Cited by 18
Metadata
- Authors
- Cicognola, C., Brinkmalm, G., Wahlgren, J., Portelius, E., Gobom, J., Cullen, N. C., Hansson, O., Parnetti, L., Constantinescu, R., Wildsmith, K., Chen, H.-H., Beach, T. G., Lashley, T., Zetterberg, H., Blennow, K., & Höglund, K.
- Affiliations
- University of Gothenburg (SE)
- Sahlgrenska University Hospital (SE)
- University of Pennsylvania (US)
- Lund University (SE)
- University of Perugia (IT)
- Genentech (US)
- Banner Sun Health Research Institute (US)
- National Hospital for Neurology and Neurosurgery (GB)
- Corresponding author
- Cicognola, Claudia
- ORCID
- Venue
- Acta Neuropathologica
- Published
- 2018-12-13
- Volume
- 137
- Issue
- 2
- Pages
- 279-296
- ISSN
- 0001-6322 (ISSN-L)
- 1432-0533
- PMC
- PMC6514201
- OpenAlex
- W2904580289
- Cited by
- 168
- References
- 44
- Citations by year
- 2026: 11 · 2025: 15 · 2024: 18 · 2023: 23 · 2022: 18 · 2021: 29 · 2020: 36 · 2019: 17
- FWCI
- 14.06
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Acta Neuropathologica (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Funders
- Vetenskapsrådet (-)
- European Research Council (-)
- Torsten Söderbergs Stiftelse (-)
- Knut och Alice Wallenbergs Stiftelse (-)
- Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse (-)
- Stiftelsen för Gamla Tjänarinnor (-)
- Ågrens Stiftelse (-)
- Swedish Alzheimer's Foundation (-)
- Swedish Brain Foundation (-)
- National Institute of Neurological Disorders and Stroke (U24 NS072026)
- National Institute on Aging (P30 AG19610)
- Arizona Department of Health Services (211002)
- Arizona Biomedical Research Commission (4001, 0011, 05-901, 1001)
- Michael J. Fox Foundation for Parkinson's Research (-)
- Reta Lila Weston Institute for Neurological Studies (-)
- Progressive Supranuclear Palsy Association (-)
- Alzheimer's Research UK (-)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- cerebrospinal fluid biomarkers, Alzheimer's disease, neurofibrillary tangles, cognitive decline, mild cognitive impairment, extracellular vesicles, neurofibrillary pathology, tau phosphorylation, amyloid-beta, prion protein, anti-tau antibodies, immunoassay, AChE inhibitors
- MeSH terms
- Aged, Alzheimer Disease, Brain, Female, Humans, Male, Peptide Fragments, Cohort Studies, Biomarkers, Amyloid beta-Peptides, tau Proteins, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.